Miguel Regueiro, MD

Cleveland Clinic

Poster(s):

• P2690 - Impact of Mirikizumab on Clinically Meaningful Improvements in Fatigue as Measured by FACIT-F in Patients With Moderately to Severely Active Crohn’s Disease
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET

• P2691 - Improvement in Fatigue With Mirikizumab Therapy and Associations With Clinical Outcomes in Patients With Moderately to Severely Active Crohn’s Disease: Results From the PHASE 3 VIVID-1 Study
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET

• P4257 - Disease Characterization and Safety Contextualization in Patients with Ulcerative Colitis Using a Healthcare Administrative Database in the United States
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET